Welcome to The Pharma Letter Podcast for a promotional episode, sponsored by Janssen, where we will deep dive into barriers and challenges in treating major depressive disorder (MDD), and finish with a few reasons for optimism.
Are you a healthcare professional?
The Pharma Letter Podcast
The need for change for major depressive disorder patients
Welcome to The Pharma Letter Podcast for a promotional episode, sponsored by Janssen, where we will deep dive into barriers and challenges in treating major depressive disorder (MDD), and finish with a few reasons for optimism.
In this week’s episode, we will discuss the current unmet medical need in MDD as well as insights and learnings from the ESCAPE-TRD Phase 3b study for SPRAVATO®▼ (esketamine nasal spray [NS]) with two leading experts in the field.
We speak to the principal investigator, Frankfurt University Hospital’s Professor Andreas Reif, and Professor Roger McIntyre, Head of Mood Disorders Psychopharmacology unit at the University Health Network in Toronto, Canada.
Professor Reif and Professor McIntyre have been renumerated for their participation in the podcast.
Adverse events should be reported. ▼ This medicinal product is subject to additional monitoring, and it is therefore important to report any suspected adverse events related to this medicinal product. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Janssen-Cilag Limited on 01494 567447 or at dsafety@its.jnj.com.
Wang, G et al. Neuropsychiatr Dis Treat. 2020;16(16):221-234
Mrazek DA et al. Psychiatr Serv. 2014;65(8):977-987.
Amos T et al. J Clin Psychiatr. 2018;79(2):17m11725.
Souery D et al. J Clin Psychiatry. 2007;68:1062–70.
Lopez Munoz et al. Curr Pharm Des. 2009; 15 (14):1563-86.
A long-term comparison of esketamine nasal spray versus quetiapine extended release, both in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor, in participants with treatment resistant major depressive disorder (ESCAPE-TRD). NCT 04338321. Clinicaltrials.gov 2023. Available at: https://clinicaltrials.gov/ct2/show/NCT04338321?term=escape-trd&draw=2&rank=1 [Accessed November 2023].
Heerlein, K et al. Most Common Treatments in Patients with Treatment Resistant Depression Based on European Cohort Study Real-World Evidence. Presented at ISPOR 2022, November 6-9. Poster HSD28.